Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Abituzumab 250 mg	10
Overall Study	STARTED	Abituzumab 500 mg	13
Overall Study	STARTED	Abituzumab 1000 mg	8
Overall Study	STARTED	Abituzumab 1500 mg	10
Overall Study	COMPLETED	Abituzumab 250 mg	10
Overall Study	COMPLETED	Abituzumab 500 mg	13
Overall Study	COMPLETED	Abituzumab 1000 mg	8
Overall Study	COMPLETED	Abituzumab 1500 mg	10
Overall Study	NOT COMPLETED	Abituzumab 250 mg	0
Overall Study	NOT COMPLETED	Abituzumab 500 mg	0
Overall Study	NOT COMPLETED	Abituzumab 1000 mg	0
Overall Study	NOT COMPLETED	Abituzumab 1500 mg	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00848510/flow